1
|
Lu J, Li J, Hu Y, Guo Z, Sun D, Wang P, Guo K, Duan DD, Gao S, Jiang J, Wang J, Liu P. Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation. Acta Pharm Sin B 2019; 9:782-793. [PMID: 31384538 PMCID: PMC6663922 DOI: 10.1016/j.apsb.2018.10.008] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2018] [Revised: 09/26/2018] [Accepted: 10/09/2018] [Indexed: 01/13/2023] Open
Abstract
The clinical application of doxorubicin (DOX) in cancer chemotherapy is limited by its life-threatening cardiotoxic effects. Chrysophanol (CHR), an anthraquinone compound isolated from the rhizome of Rheum palmatum L., is considered to play a broad role in a variety of biological processes. However, the effects of CHR׳s cardioprotection in DOX-induced cardiomyopathy is poorly understood. In this study, we found that the cardiac apoptosis, mitochondrial injury and cellular PARylation levels were significantly increased in H9C2 cells treated by Dox, while these effects were suppressed by CHR. Similar results were observed when PARP1 activity was suppressed by its inhibitors 3-aminobenzamide (3AB) and ABT888. Ectopic expression of PARP1 effectively blocked this CHR׳s cardioprotection against DOX-induced cardiomyocyte injury in H9C2 cells. Furthermore, pre-administration with both CHR and 3AB relieved DOX-induced cardiac apoptosis, mitochondrial impairment and heart dysfunction in Sprague-Dawley rat model. These results revealed that CHR protects against DOX-induced cardiotoxicity by suppressing cellular PARylation and provided critical evidence that PARylation may be a novel target for DOX-induced cardiomyopathy.
Collapse
Key Words
- 3AB, 3-aminobenzamide
- ADR, adriamycin
- ANOVA, one-way analysis of variance
- Apoptosis
- CHR, chrysophanol
- CMC-Na, sodium carboxymethyl
- CO, cardiac output
- Cardiotoxicity
- Chrysophanol
- Cyt c, Cytochrome c
- DOX, doxorubicin
- Doxorubicin
- EF, ejection fraction
- FBS, fetal bovine serum
- FS, fractional shortening
- HE, hematoxylin-eosin
- HR, heart rate
- IVSd, end-diastolic interventricular septum
- IVSs, end-systolic interventricular septum
- LV, end-systolic volume
- LVEDV, LV end-diastolic volume
- LVIDd, LV end-diastolic internal diameter
- LVIDs, LV end-systolic internal diameter
- LVPWd, LV end-diastolic posterior wall thickness
- LVPWs, LV end-systolic posterior wall thickness
- Mitochondria
- NS, normal saline
- PAR, polymers of ADP-ribose
- PARP1, poly(ADP-ribose) polymerase 1
- PARylated, poly(ADP-ribosyl)ated
- PARylation
- PARylation, poly(ADP-ribosyl)ation
- PBS, phosphate-buffered saline
- RCR, respiratory control ratio
- ROS, reactive oxygen species
- Rh123, rhodamine 123
- SD, Sprague–Dawley
- TUNEL, TdT-mediated dUTP nick end labeling
- VDAC1, voltage dependent anion channel 1
Collapse
|
2
|
Hu Y, Guo Z, Lu J, Wang P, Sun S, Zhang Y, Li J, Zheng Q, Guo K, Wang J, Jiang J, Liu P. sFRP1 has a biphasic effect on doxorubicin-induced cardiotoxicity in a cellular location-dependent manner in NRCMs and Rats. Arch Toxicol 2018; 93:533-546. [PMID: 30377735 DOI: 10.1007/s00204-018-2342-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Accepted: 10/23/2018] [Indexed: 12/22/2022]
Abstract
Doxorubicin (Dox) is an effective anticancer drug, however, its clinical application is restricted by the life-threatening cardiotoxic effects. Secreted Frizzled-related protein 1 (sFRP1) has been reported to participate in both the cancer and cardiovascular diseases and was one of the differential expression genes in normal hearts compared with Dox-treated hearts. Thus, it is important to reveal the potential role of sFRP1 in Dox-induced cardiotoxicity. Here, we show that sFRP1 has a biphasic effect on Dox-induced cardiotoxicity in a location-dependent manner. The secretion of sFRP1 was significantly increased in Dox-treated neonatal rat cardiomyocytes (NRCMs) (1 µM) and SD rats (5 mg/kg/injection at day 1, 5, and 9, i.p.). Adding the anti-sFRP1 antibody (0.5 µg/ml) and inhibiting sFRP1 secretion by caffeine (5 mM) both relieved Dox-induced cardiotoxicity through activating Wnt/β-catenin signaling, whereas increasing the secretion of sFRP1 by heparin (100 µg/ml) had the opposite effect. The intracellular level of sFRP1 was significantly decreased after Dox treatment both in vitro and in vivo. Knockdown of sFRP1 by sgRNA aggravated Dox-induced cardiotoxicity, while moderate overexpression of sFRP1 by Ad-sFRP1 exhibited protective effect. Besides, poly(ADP-ribosyl) polymerase-1 (PARP1) was screened as an interacting partner of sFRP1 in NRCMs by mass spectrometry. Our results suggested that the intracellular sFRP1 protected NRCMs from Dox-induced cardiotoxicity by interacting with PARP1. Thus, our results provide a novel evidence that sFRP1 has a biphasic effect on Dox-induced cardiotoxicity. In addition, the oversecretion of sFRP1 might be used as a biomarker to indicate the occurrence of cardiotoxicity induced by Dox treatment.
Collapse
Affiliation(s)
- Yuehuai Hu
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China
| | - Zhen Guo
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China
| | - Jing Lu
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China.
| | - Panxia Wang
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China
| | - Shuya Sun
- School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, People's Republic of China
| | - Yiqiang Zhang
- Division of Cardiology, Department of Medicine, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98109, USA
| | - Jingyan Li
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China
| | - Qiyao Zheng
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China
| | - Kaiteng Guo
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China
| | - Junjian Wang
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China
| | - Jianmin Jiang
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China.
| | - Peiqing Liu
- School of Pharmaceutical Sciences, Guangzhou Higher Education Mega Center, Sun Yat-sen University, 132 East Waihuan Road, Guangzhou, 510006, People's Republic of China.
| |
Collapse
|